Ikena Oncology reports initial IK-175 clinical data: 20% ORR in combination with nivolumab in urothelial carcinoma

ImageneBio, Inc.

IK-175 combo with nivolumab: 20% ORR, 40% DCR in heavily pretreated urothelial carcinoma patients who progressed on checkpoint inhibitors.
Monotherapy: 10% ORR, 20% DCR; one confirmed partial response with duration of response 14.9 months and ongoing.
Dose escalation in solid tumors: prolonged stable disease up to >19 months; MTD not reached; 1200mg selected as expansion dose.
Well tolerated with low-grade rash, nausea (monotherapy) and fatigue, dysgeusia (combo); only 2 serious adverse events.
Program in collaboration with Bristol Myers Squibb; opt-in decision eligible through early 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.